Optus Pharmaceutical Co. Ltd. (131030) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Optus Pharmaceutical Co. Ltd. (131030:KRX), powered by AI.

Current Price
₩10,800
P/E Ratio
16.0
Market Cap
174.5B
Sector
Healthcare
What is the Optus Pharmaceutical Co. Ltd. stock price forecast?

Optus Pharmaceutical Co. Ltd. is currently trading at ₩10,800. View real-time AI analysis on Alpha Lenz.

What is Optus Pharmaceutical Co. Ltd. insider trading activity?

View the latest insider trading data for Optus Pharmaceutical Co. Ltd. on Alpha Lenz.

What is Optus Pharmaceutical Co. Ltd.'s P/E ratio?

Optus Pharmaceutical Co. Ltd.'s P/E ratio is 16.0.

Optus Pharmaceutical Co. Ltd.

₩10.80K
KRX131030
Ask about Optus Pharmaceutical Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Optus Pharmaceutical Co. Ltd. trades at a P/E of 16.0 (fair value) with modest ROE of 7.4%. 3Y revenue CAGR of 12.6% highlights clear growth momentum.

Ask for details

Company Overview

Optus Pharmaceutical Co. Ltd. is a company engaged in the development, manufacturing, and marketing of pharmaceutical products. Its primary function is to provide innovative and effective medications that cater to a wide range of medical needs. Optus Pharmaceutical focuses on both prescription drugs and over-the-counter pharmaceuticals, serving various therapeutic areas such as oncology, cardiovascular diseases, and infectious diseases. With a commitment to research and development, the company aims to introduce breakthrough drugs that enhance patient care and address unmet medical needs. Optus Pharmaceutical plays a significant role in the healthcare sector by collaborating with healthcare professionals, regulatory bodies, and research institutions. Its operations not only contribute to advancements in medical treatments but also have an impact on the pharmaceutical supply chain, affecting distribution channels worldwide. By consistently prioritizing quality and efficacy, Optus Pharmaceutical Co. Ltd. maintains its position as an important player in the global pharmaceutical industry.

CEO심상호
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

(FY 2024)

Profile

Market Cap₩174.45B
Revenue₩81.90B
Shares Out16.15M
Employees0

Margins

Gross54.59%
EBITDA18.35%
Operating10.49%
Pre-Tax14.75%
Net12.59%

Valuation

P/E16.00
P/B1.15
EV/Sales2.01
EV/EBITDA9.28
P/FCF-9.80

Growth (CAGR)

Rev 3Yr12.64%
Rev 5Yr6.27%
Op Inc 3Yr-6.40%
Op Inc 5Yr-10.78%
Net Inc 3Yr1.39%
Net Inc 5Yr-6.72%

Returns

ROA6.53%
ROE7.41%
ROIC7.71%

Financial Health

Cash & Cash Equivalents₩26.91B
Net Debt₩-4.14B
Debt/Equity15.84%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Optus Pharmaceutical Co. Ltd. (Healthcare) Stock Forecast & Analysis ₩10,800 | Alpha Lenz